D-萤光素作用机制 - Medchemexpress - MCE中国

1、Product Data SheetD-LuciferinCat. No.: HY-12591ACAS No.: 2591-17-5分式: CHNOS分量: 280.32作靶点: Others作通路: Others储存式: 4C, protect from light* In solvent : -80C, 6 months; -20C, 1 month (protect from light)溶解性数据体外实验 DMSO : 125 mg/mL (445.92 mM; Need ultrasonic)H2O : 0.1 mg/mL (insoluble)H2O : 0.1 mg/mL (in

2、soluble)SolventMass1 mg 5 mg 10 mgConcentration制备储备液1 mM 3.5674 mL 17.8368 mL 35.6735 mL5 mM 0.7135 mL 3.5674 mL 7.1347 mL10 mM 0.3567 mL 1.7837 mL 3.5674 mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存式和期限：-80C, 6 months; -20C, 1 month (protect from light)。-80C 储存时，请在 6 个内使，-20C 储存时，

3、请在 1 个内使。体内实验请根据您的实验动物和给药式选择适当的溶解案。以下溶解案都请先按照 In Vitro 式配制澄清的储备液，再依次添加助溶剂：为保证实验结果的可靠性，澄 的储备液可以根据储存条件，适当保存；体内实验的作液，建议您现现配，当天使； 以下溶剂前显的百分 指该溶剂在您配制终溶液中的体积占；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的式助溶1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (7.42 mM); Clear solution此案可获得 2.08

4、mg/mL (7.42 mM，饱和度未知) 的澄清溶液。以 1 mL 作液为例，取 100 L 20.8 mg/mL 的澄 DMSO 储备液加到 400 L PEG300 中，混合均匀；向上述体系中加50 L Tween-80，混合均匀；然后继续加 450 L 理盐定容 1 mL。2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (7.42 mM); Clear solution此案可获得 2.08 mg/mL (7.42 mM，饱和度未知) 的澄清溶液。Page 1 of 2 www.MedChem

5、E以 1 mL 作液为例，取 100 L 20.8 mg/mL 的澄均匀。DMSO 储备液加到 900 L 20% 的 SBE-CD 理盐溶液中，混合BIOLOGICAL ACTIVITY物活性 D-luciferin萤光素酶的天然底物，可催化物发光昆产典型的黄绿光。体外研究 D-luciferin is the natural substrate of the enzyme luciferase (Luc), that catalyzes the production of the typicalyellowgreen light of fireflies.The present revie

6、w covers the synthesis of D-luciferin and derivatives or analogues thatare substrates or inhibitors of the luciferase from the American firefly Photinus pyralis, the enzyme more frequentlyused in techniques of in vitro and optical imaging1.Thaw D-Luciferin (either Potassium or Sodium Salt) at room t

7、emperature and dissolve in DPBS (no calcium ormagnesium) to a final concentration of 15 mg/mL. Pre-wet a 0.22 m filter by drawing through 5-10 mL of sterile H2Oand discard water. Sterilize the D-Luciferin solution through the prepared 0.22 m syringe filter.体内研究 Bioluminescence imaging (BLI) using th

8、e firefly luciferase (Fluc) as a reporter gene and D-luciferin as a substrate iscurrently the most widely employed technique. The total signal intensity is plotted against the time after D-luciferininjection to generate a time-intensity curve. In addition to the peak signal, the signals at fixed tim

9、e points (5, 10, 15,and 20 min) after D-luciferin injection are determined as alternatives to the peak signal. The signal in a given time-intensity curve is normalized for the peak signal in the curve to represent the pattern of temporal changes after D-luciferin injection2.Inject with 10 L of D-luc

10、iferin (intraperitoneally or intravenously) stock solution per gram of body weight: normally200 L for a 20 g mouse for a standard 150 mg/kg injection.PROTOCOLAnimal Mice2Administration 2 In vivo BLI is performed using a cooled charge-coupled device camera system (IVIS Imaging System 100) 3, 5, 7, 10

11、,12, 14, 19, 21, 24, and 28 days after the inoculation of HCT116-Luc cells. Mice are injected with 75 mg/kg D-luciferinin 100 L of phosphate-buffered saline subcutaneously near the scapula and were placed in the light-tight chamberof the imaging system under isoflurane anesthesia. Beginning 5 min af

12、ter injection, dorsal luminescent images withan exposure time of 1 s are acquired sequentially at a rate of one image per min until 20 min after D-luciferininjection. Data acquisition is continued until 40 min postinjection on days 3 or 5 and until 25 min on day 7, because ofthe prolonged time cours

13、e of light emission. Binning is 4 and the field of view is 15 cm.MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 J Leukoc Biol. 2019 Jun 18. Biomed Pharmacother. 2019 Sep;117:109126. Int J Oncol. 2020 Jan.See more customer validations on HYP

14、ERLINK www.MedChemE www.MedChemEPage 2 of 3 www.MedChemEREFERENCES1. Giuseppe Meroni, et al. D-Luciferin, derivatives and analogues: synthesis and in vitro/in vivo luciferase-catalyzed bioluminescent activity. ARKIVOC 2009(i) 265-288.2. Inoue Y, et al. Timing of imaging after d-luciferin injection affects the longitudinal assessment of tumor growthusing in vivo bioluminescence imaging.Int J Biomed Imaging. 2010;2010:471408.McePd